Resources Year All 2019 2018 2017 2016 2015 2014 2013 2012 2010 Go Search Presentation Single Agent Oral Selinexor in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Phase 2b SADAL Study PDF (4.14 MB) Read MorePresentation Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer PDF (507.62 KB) Read MorePaper Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis External Link Read MorePaper Selective Inhibition of Nuclear Export with Selinexor in Patients with Non-Hodgkin’s Lymphoma External Link Read MorePaper A Phase I Clinical Trial of Single-Agent Selinexor in Acute Myeloid Leukemia External Link Read MorePresentation Phase 1B Study to Evaluate the Safety of Selinexor in Combination with Multiple Standard Chemotherapy Agents in Patients with Advanced Malignancies PDF (1.02 MB) Read MorePaper Selective inhibitor of nuclear export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3 PDF (19.01 MB) Read MorePaper Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IκB and down-regulation of survivin External Link Read MorePaper Inhibition of exportin-1 function results in rapid cell cycle associated DNA damage in cancer cells PDF (4.30 MB) Read MorePresentation The Enhancement of Anti-Tumor Activities of Selinexor when Combined with Immune Checkpoint Inhibitors PDF (9.27 MB) Read More Previous 1 2 3 4 5 6 … 22 Next